Biosimilars and Infusion Center Margins: What Lenders Weigh
Biosimilars are changing the economics of infused therapies, and infusion center margins are feeling the effect. As lower-cost alternatives to established biologic drugs become available and payers encourage their use, the revenue a center earns on each dose can change, sometimes significantly. For owners, buyers and lenders, understanding that shift is now part of evaluating any infusion business.
This article explains how biosimilars can affect buy-and-bill economics, why lenders pay attention and what owners can do to plan. It does not address clinical decisions, which belong to patients and their physicians. Reimbursement and billing rules vary by payer, and nothing here is clinical, legal, tax, billing or compliance advice.
How Buy-and-Bill Margins Work
In a buy-and-bill model, the center purchases a drug, administers it and is reimbursed by the payer. The drug margin is the difference between what the center pays to acquire the drug and what it is paid for it. Centers also earn separate payment for administration and related services.
Many reimbursement methods are tied in some way to the price of the drug. When that is the case, a lower-priced product may produce a smaller margin in dollar terms, even if the percentage relationship is similar. That dynamic is at the heart of how biosimilars can affect centers.
How Biosimilars Can Affect Infusion Center Margins
- Lower reimbursement per dose: as payers shift to lower-priced products, dollar revenue per infusion may fall
- Changing acquisition costs: purchasing terms for reference products and biosimilars may differ
- Payer preferred-product policies: some payers require or favor specific products, which can force centers to stock several versions
- Inventory complexity: carrying multiple products for the same therapy can increase waste and tie up cash
- Administrative work: product switches may require new authorizations and documentation
Not every effect is negative. Lower-priced drugs reduce the cash tied up in each dose, which can ease the buy-and-bill cash gap. Broader access may also increase patient volume for some therapies.
Why Cash Flow May Improve Even as Margins Shrink
When a center buys a lower-cost drug, it spends less up front for each infusion. That can reduce the working capital needed to support the same number of patients. Our article on infusion center working capital explains how drug costs drive the cash cycle and how centers finance it.
The trade-off is that the center may earn less per dose, so it may need more volume, better service revenue or lower operating costs to maintain overall profit.
What Lenders Weigh
Lenders reviewing an infusion center increasingly look beyond historical revenue to how margins may change. They may consider:
- Concentration of revenue in therapies where biosimilars are available or expected
- Historical drug margins compared with administration and service revenue
- Payer mix and each major payer’s product policies
- Inventory practices and how the center manages multiple products
- Whether projections reflect realistic margin trends rather than past results
- Owner plans to diversify therapies and referral sources
A center with heavy reliance on a single high-margin therapy may be viewed as higher risk if that therapy faces lower-cost competition. Our overview of infusion center loan requirements explains how lenders review cash flow more broadly.
Building Margin Changes Into Projections
Projections that simply repeat last year’s drug margins may not persuade a lender. A more credible approach models each major therapy separately, considers how payer policies may shift product mix and includes a downside case with lower margins per dose. Showing that the center can still cover its obligations under that scenario can strengthen a financing request.
Implications for Buyers and Valuation
Buyers should look carefully at which therapies drive a center’s earnings and whether those margins are likely to hold. A price based on historical results may not reflect what the center can earn after a shift to lower-cost products. Our article on infusion center valuation explains how buyers and lenders adjust for risks like this.
How Owners Can Protect Infusion Center Margins
Owners cannot control drug pricing, but they can manage how changes affect the business:
- Track margins by therapy, product and payer on a regular basis
- Review payer product policies and plan inventory accordingly
- Diversify therapies and referral sources
- Strengthen administration and service revenue through efficient scheduling and chair utilization
- Reduce waste through careful purchasing and inventory controls
- Work with qualified billing professionals to keep authorizations and documentation current
Our article on how profitable an infusion center can be covers the broader drivers of profit beyond drug margins.
Financing Through Margin Changes
When margins compress, some centers find their existing debt harder to carry. Owners in that position may want to review whether a different structure fits better. Our article on infusion center refinance options explains what lenders consider.
A properly sized line of credit can also help centers adjust inventory as product mix changes. Learn more about our infusion therapy working capital and lines of credit. Every loan is subject to approval, and nothing here is a commitment to lend.
Final Thoughts
Biosimilars can reshape infusion center margins, lowering dollar revenue per dose while also reducing the cash tied up in inventory. Lenders and buyers are paying closer attention to therapy concentration and margin trends. Owners who track margins by product and payer, diversify their therapy mix and plan inventory carefully are better positioned to adapt and to present a credible picture to lenders.
US Medical Funding helps infusion therapy owners finance their centers with a realistic view of changing margins. Learn more about our full range of infusion therapy center financing options.
